Dr. Saadvik Raghuram y

3.7K posts

Dr. Saadvik Raghuram y banner
Dr. Saadvik Raghuram y

Dr. Saadvik Raghuram y

@saadvikdr

Head of department Medical Oncology | Arete institute of oncology | Arete Hospitals

hyderabad Katılım Nisan 2011
333 Takip Edilen702 Takipçiler
Dr. Saadvik Raghuram y retweetledi
Anuradha Tiwari
Anuradha Tiwari@talk2anuradha·
Nitin Gadkari ji says "A new AI-driven toll system will capture photos of number plates & deduct toll amount directly from bank accounts". So why can’t we use same technology to capture photos of potholes & deduct salaries of govt employees? Accountability can't be one sided!
English
1.5K
10.3K
35.6K
919.1K
Dr. Saadvik Raghuram y retweetledi
Raghav Chadha
Raghav Chadha@raghav_chadha·
₹19,000 crore. That is what Banks collected in last 3 years just for not maintaining ‘Minimum Account Balance.’ Not from the rich. Not from big borrowers. From the poorest accounts in the system. Their crime? They didn’t have enough money. A farmer misses the minimum balance - Penalty. A pensioner withdraws money for medicine - Penalty. A daily wage worker falls short by a few hundred rupees - Penalty. The poor keep money in banks for safety. Not to be quietly fined for being poor. Financial inclusion should protect small savings, not punish small balances. In Parliament today I proposed ending minimum balance penalties so the banking system stops charging people for their poverty.
English
2K
13.3K
47.6K
1M
Dr. Saadvik Raghuram y retweetledi
Daniel Berglind, PhD
Daniel Berglind, PhD@DanielBerglind·
💉 GLP-1 works—but muscles decide the outcome. 🔬 A new meta-analysis (18 RCTs, ~3,800 participants) shows significant weight regain and worsening metabolic health after GLP-1 discontinuation thelancet.com/journals/eclin…
English
14
85
465
47.1K
Dr. Saadvik Raghuram y retweetledi
Priyanka Chaturvedi🇮🇳
Priyanka Chaturvedi🇮🇳@priyankac19·
What’s the point in releasing such photos of the Indigo CEO sitting with folded hands, when the truth is that it is the government that has buckled and rolled back the FDTL norms and has been unsuccessful in taking stringent action for disruption in the skies? The culprit isn’t the airline but those who turned a blind eye to the market capture& allowed things to fester till this point
Priyanka Chaturvedi🇮🇳 tweet media
English
292
744
4.3K
155.3K
Dr. Saadvik Raghuram y
Dr. Saadvik Raghuram y@saadvikdr·
New NEJM data is a breakthrough! A single dose of the HPV vaccine is as protective as two doses against HPV16 & 18 — responsible for most cervical cancers. ✔ 98% effectiveness ✔ Equal protection for bivalent & nonavalent vaccines ✔ Major boost for global vaccination access
Dr. Saadvik Raghuram y tweet media
English
0
0
0
85
Dr. Saadvik Raghuram y
Dr. Saadvik Raghuram y@saadvikdr·
India’s AQI crisis is a health emergency. PM2.5 doesn’t just irritate lungs — it enters the bloodstream, causes DNA damage & increases cancer risk. ✔ Linked with lung, bladder cancer ✔ WHO: 99% people breathe unhealthy air ✔ PM2.5 triggers early lung cancer in non-smokers
Dr. Saadvik Raghuram y tweet media
English
0
0
0
63
Dr. Saadvik Raghuram y retweetledi
Oncology Brothers
Oncology Brothers@OncBrothers·
Durvalumab + FLOT—>✂️—>Durva now @FDAOncology ✅ for resectable GEJ/Gastric Ca based off #MATTERHORN study. - ⭐️ Improved OS in all comers (HR: 0.78) - Rate of✂️, # of FLOT, and AEs (Gr 3 & 4: 71%) similar in both arms. #OncTwitter @OncoAlert @OncUpdates @YJanjigianMD 👏👏
Oncology Brothers tweet mediaOncology Brothers tweet mediaOncology Brothers tweet mediaOncology Brothers tweet media
ASCO@ASCO

5th Plenary #ASCO25: #MATTERHORN Ph III, Durvalumab + FLOT—>✂️—>Durva vs NeoAdj FLOT in resectable GEJ/Gastric Ca. - 2yr EFS 67% vs 59% (HR: 0.71). Improvement regardless of PDL1 - 2yr OS 76% vs 70%. mOS NR - Rate of✂️& number of FLOT similar in both arms - D-FLOT new SoC!

English
6
31
75
18.1K
Dr. Saadvik Raghuram y retweetledi
Oncology Brothers
Oncology Brothers@OncBrothers·
PeriOP Enfortumab + Pembro in cis-ineligible MIBC followed by postOP EV + Pembro now @US_FDA ✅ based off #KEYNOTE905 #EV303 study: - EFS At 2yrs: 74.7% vs. 39.4% - EFS HR: 0.40 - OS at 2yrs: 79.7% vs. 63.1 (HR: 0.50) #OncTwitter #MedTwitter
Oncology Brothers tweet mediaOncology Brothers tweet mediaOncology Brothers tweet mediaOncology Brothers tweet media
English
7
39
109
12.9K
OncUpdates
OncUpdates@OncUpdates·
🚨 NEW FDA Approval ‼️ Pembrolizumab + Enfortumab Vedotin (EV) approved by FDA for neoadjuvant + adjuvant therapy in cisplatin-ineligible MIBC patients ⭐️FDA approval based off KEYNOTE-905/EV-303 presented @myESMO. 🔑 highlights 👇 #OncTwitter #MedTwitter @OncBrothers
OncUpdates tweet media
OncUpdates@OncUpdates

#ESMO25 Highlights! #KEYNOTE905: PeriOP EV + Pembro in cis-ineligible MIBC followed by postOP EV + Pembro: 🎯EFS At 2yrs: 74.7% vs. 39.4% 📈EFS HR: 0.40 ✅OS at 2yrs: 79.7% vs. 63.1 (HR: 0.50) #MedTwitter #OncTwitter #OncTwitter #MedX

English
1
0
5
479
Dr. Saadvik Raghuram y
Dr. Saadvik Raghuram y@saadvikdr·
The FDA’s new “Plausible Mechanism Pathway” is a major step forward. It enables mutation-specific, bespoke therapies when trials aren’t feasible — a huge breakthrough for oncology & rare diseases.Faster access. Strong biological rationale. nejm.org/doi/full/10.10…
English
0
0
0
46
Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO@neerajaiims·
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit asco.org/election to learn more about the candidates and place your vote! Thank you!!
Neeraj Agarwal, MD, FASCO tweet media
English
20
99
241
149.1K